Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
July 01, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
May 08, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
May 02, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
April 18, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
March 04, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
February 29, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
February 27, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
February 22, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 08, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
December 05, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
December 04, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 29, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
November 27, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
November 16, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 02, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
November 01, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
September 11, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 02, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
June 05, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
May 30, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting
May 25, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
May 24, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
May 11, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GSK
SWTX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.